Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns

Stroke and Vascular Neurology

article

Yi Dong¹  Yi Sui²  Xin Cheng¹  David Z Wang⁴ 

[1] Department of Neurology , Huashan Hospital Fudan University;Department of Neurology, Shenyang Brain Hospital , Shenyang Medical College;Department of Neurology , The First People's Hospital of Shenyang;Department of Neurology , Barrow Neurological Institute

关键词: cerebral infarction;    stroke;    clinical trial;    thrombolysis;    thrombectomy;   

DOI  :  10.1136/svn-2021-001321

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Tenecteplase (TNKase, TNK-tPA or TNK)is a thrombolytic agent derived from thetissue plasminogen activator (tPA). It is a527-amino acid glycoprotein developed byreplacing three amino acids at the T, N andK positions of the glycoprotein structure oftPA under genetic recombinant technology.After replacing threonine 103 with asparagine, asparagine 117 with glutamine and atetra-alanine at amino acids 296–299, TNKis about eightfold more potent in dissolvingclot, 80-fold higher resistance to plasminogenactivator inhibitor-1 and 14-fold enhancedrelative fibrin specificity, and with a longerhalf-life (20min).1 Hence, TNK is administered as a single intravenous bolus.

【 授权许可】

CC BY-NC|CC BY|CC BY-NC-ND